Announces CFO transition Announces CFO transition
Continue reading here:
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246 (also known as FOR46), a potential first-in-class anti-CD46 antibody drug conjugate (ADC) with an MMAE-containing payload, in a dose-escalation and dose-expansion trial enrolling patients with metastatic castration-resistant prostate cancer (mCRPC) whose tumors have progressed on at least one androgen receptor-signaling inhibitor (ARSI).
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on April 1, 2024, the Compensation Committee of Praxis’ Board of Directors granted non-qualified stock option awards to purchase 300 shares of its common stock and restricted stock unit awards covering 225 shares of its common stock to one new non-executive employee under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the “2024 Inducement Plan”). The stock options and restricted stock units were granted as inducements material to the employee’s entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
Follow this link:
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 02, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“Centogene”, “we”, or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notification letter dated March 27, 2024, from the Nasdaq Stock Market LLC Listing Qualifications Department, indicating that the Company was not in compliance with the minimum bid price requirement set forth in Rule 5450(a)(1) of the Nasdaq Listing Rules since the closing bid price for the Company's common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days (from February 12 through March 26, 2024). Nasdaq Rule 5450(a)(1) requires the shares to maintain a minimum bid price of US$1.00 per share, and Nasdaq Rule 5810(c)(3)(A) provides that failure to meet such a requirement exists when the bid price of the shares is below US$1.00 for a period of 30 consecutive business days.
Excerpt from:
CENTOGENE Receives Nasdaq Non-Compliance Notice
REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the 23rd Annual Needham Virtual Healthcare Conference at 11am EDT on April 8, 2024.
Read more:
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Leiden, The Netherlands, April 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of April:
See the rest here:
Pharming Group to participate in April investor conferences
Addex receives CHF5M and 20% share of Neurosterix
The rest is here:
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
Here is the original post:
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin
LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) has been selected for an oral presentation at the American Society of Clinical Oncology (2024 ASCO) Annual Meeting to be held May 31 – June 4, 2024 in Chicago. The oral presentation will be presented by one of the investigators of this clinical trial, Gilbert Youssef, M.D., Attending Physician at Harvard Medical School, Center for Neuro-Oncology at Dana-Farber Cancer Institute and Brigham and Women's Hospital.
Read this article:
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024...